Results 121 to 130 of about 7,581 (239)

Cost-effectiveness analysis of CTZ/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan

BMC Health Services Research
Background Resistant bacterial infections, particularly those caused by gram-negative pathogens, are associated with high mortality and economic burdens.
Risako Takaya, Nobuyoshi Mori, Eiko Saito, Sachiko Ohde   +3 more
doaj   +1 more source

Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria [PDF]

, 2016
Mark D. Gonzalez, Allison R. McMullen, Meghan A. Wallace, Matthew P. Crotty, David J. Ritchie, Carey‐Ann D. Burnham   +5 more
openalex   +1 more source

In Vitro Susceptibility of Multidrug-resistant Pseudomonas Aeruginosa Following Treatment-Emergent Resistance to Ceftolozane-Tazobactam [PDF]

, 2020
Background: Multidrug-resistant (MDR) Pseudomonas aeruginosa is a major public health threat. Treatment with ceftolozane-tazobactam improves patient outcomes compared to salvage therapy; however, resistance has emerged in ~15% of patients following ...
Rubio, Abigail
core  

Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination

Infection and Drug Resistance, 2013
Mai-Chi Hong1, Donald I Hsu1,2, Mark Bounthavong3,41Department of Pharmacy Practice and Administration, Western University of Health Sciences, Pomona, 2Department of Pharmacy, St Joseph Hospital, Orange, 3Department of Pharmacy, Veterans Affairs San ...
Hong MC, Hsu DI, Bounthavong M
doaj  

1282. Ceftolozane/Tazobactam Use in Critically Ill Patients Receiving Intermittent or Continuous Renal Replacement Therapy [PDF]

, 2021
Molly J. Henry, Laura Puzniak, Kelly Harris, Trevor Van Schooneveld, Trevor Van Schooneveld, Scott Bergman, Scott Bergman   +6 more
openalex   +1 more source

Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam–β-Lactamase Inhibitor Combinations

, 2020
Alan Forrest, Judith N. Steenbergen, Patricia N. Holden, Lawrence V. Friedrich, Rachel L. Soon, Brian T. Tsuji, Pamela Kelchlin, Zackery P. Bulman, Justin R. Lenhard   +8 more
openalex   +1 more source

Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa Sequence Type 175 in a Hollow-Fiber Infection Model [PDF]

, 2018
M. Montero, Brian VanScoy, Carla López-Causapé, Haley Conde, Jonathan Adams, Concepción Segura, Laura Zamorano, Antonio Oliver, Juan Pablo Horcajada, Paul G. Ambrose   +9 more
openalex   +1 more source

Ceftolozane/Tazobactam Activity Tested Against Bacterial Bloodstream Isolates From Multiple Infection Sources [PDF]

, 2016
Leonard R Duncan, Hélio S. Sader, Robert K. Flamm, Mariana Castanheira   +3 more
openalex   +1 more source

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15) [PDF]

, 2017
Bassetti, Matteo, Castanheira, Mariana, Duncan, Leonard R., Pfaller, Michael A.   +3 more
core   +1 more source

Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections

Therapeutics and Clinical Risk Management, 2016
Stephanie E Giancola,1 Monica V Mahoney,2 Tiffany E Bias,3,4 Elizabeth B Hirsch2,51Department of Pharmacy, St Mary’s Medical Center, Huntington, WV, 2Beth Israel Deaconess Medical Center, Boston, MA, 3Hahnemann University Hospital, 4Drexel ...
Giancola SE, Mahoney MV, Bias TE, Hirsch EB   +3 more
doaj